BioInvent International AB, a biotech company involved in the discovery and development of immune-modulatory antibodies for cancer immunotherapy, reported that its early discovery partner Exelixis, Inc. has provided a notice of termination for the option and license agreement for novel antibodies for use in immuno-oncology therapeutics. The companies will collaborate on a wind-down and effective transition over the next 90 days. The news follows a recently announced corporate restructuring pr...